GluBio Therapeutics
About:
GluBio Therapeutics engages in molecular glue-targeted protein degradation drug discovery.
Website: https://www.glubiotx.com
Top Investors: Qiming Venture Partners, Legend Capital, K2VC, Lilly Asia Ventures, GL Ventures LLC
Description:
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
Total Funding Amount:
$72M
Headquarters Location:
Hangzhou, Zhejiang, China
Founded Date:
2021-01-01
Founders:
Number of Employees:
11-50
Last Funding Date:
2022-08-01
IPO Status:
Private
Industries:
© 2025 bioDAO.ai